Caris Life Sciences, Inc.
Caris Life Sciences, Inc. (Nasdaq: CAI) develops molecular profiling and data-driven solutions for precision medicine, primarily in oncology, serving physicians, patients, academic researchers, and biopharmaceutical companies. Its offerings include tissue- and blood-based sequencing and analysis to support cancer… From the company’s description.
In fiscal 2025, Caris Life Sciences, Inc. reported revenue of $812.03M and a net loss of $68.09M. Its operating margin was 5.6%, and operations generated $83.16M in cash. Over the twelve months to Sep 30, 2026, revenue was $1.05B.
Dotted labels explain each measure. is shown separately from the annual figures.
What Caris Life Sciences, Inc. does
In the company’s own words
Caris Life Sciences, Inc. (Nasdaq: CAI) develops molecular profiling and data-driven solutions for precision medicine, primarily in oncology, serving physicians, patients, academic researchers, and biopharmaceutical companies. Its offerings include tissue- and blood-based sequencing and analysis to support cancer diagnosis and therapy selection, with additional solutions in development for early detection, minimal residual disease tracking, and treatment monitoring. Caris also uses its molecular data, laboratory capabilities, and artificial intelligence tools to identify drug targets and develop therapeutics, both with biopharma partners and through its own pipeline. Its business includes the Molecular Intelligence portfolio, Caris Discovery, strategic data capabilities, and supporting laboratory, research, and commercial infrastructure. Key products and tools include MI Profile, Caris Assure, MI Cancer Seek, GPSai, FOLFIRSTai, and the developing Caris Detect assay. As of December 31, 2025, the company had sequenced more than 1 million cases and served over 6,000 U.S. ordering physicians.
Company details
- Sector
- Health Care
- Industry (SIC)
- Health Services
- Headquarters
- IRVING, TX
- Fiscal year end
- December
- CIK
- 2019410
- SIC
- 8071
Financial performance, year by year
Fiscal 2025–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Caris Life Sciences, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Caris Life Sciences, Inc. · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Caris Life Sciences, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Caris Life Sciences, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Caris Life Sciences, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Caris Life Sciences, Inc.'s last four quarterly filings that the numbers alone won't show?”